검색
Connect Biopharma Holdings Ltd
CNTB관심 목록에 추가
1.070USD
-0.145-11.93%
종가 09-23 16:00（ET）
59.62M시가총액
손실P/E TTM
장전 거래 07:02 (ET)1.080USD+0.010+0.94%
장전 거래 07:02 (ET)Connect Biopharma Holdings Ltd 정보 회사
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Connect Biopharma Holdings Ltd 프로필
종목 코드 CNTB
회사 이름Connect Biopharma Holdings Ltd
상장일Mar 19, 2021
CEOQuart (Barry D)
직원 수62
유형Ordinary Share
회계 연도 종료Mar 19
주소3580 Carmel Mountain Road, Suite 200
도시SAN DIEGO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호92130
전화18587271040
웹사이트https://www.connectbiopharm.com
종목 코드 CNTB
상장일Mar 19, 2021
CEOQuart (Barry D)
Connect Biopharma Holdings Ltd의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Lisa Peraza, CPA
Ms. Lisa Peraza, CPA
Vice President - Finance
Vice President - Finance
45.19K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
11.78K
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
86.55K
+4.32%
자주 묻는 질문
Connect Biopharma Holdings Ltd의 상위 5대 주주는 누구인가요?
Connect Biopharma Holdings Ltd의 상위 5대 주주는 다음과 같습니다: Dr. Barry D. Quart, Pharm.D.
Connect Biopharma Holdings Ltd(CNTB)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Connect Biopharma Holdings Ltd의 주식을 보유한 기관은 총 51곳이며, 이들이 보유한 주식의 총 가치는 약 29.94M로 전체 발행 주식의 52.97%를 차지합니다. 이는 2025Q4 대비 8109973.00 증가한 수치입니다.